SCHEMBL196861

SCHEMBL196861

Clc1ccc(-c2ccncc2)cc1

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GCGR P47871 4/20 0.67
LMNA P02545 2/20 0.65
MAPT P10636 1/20 0.65
LSS P48449 1/20 0.61
AKT1 P31749 5/20 0.57
KDM4E B2RXH2 1/20 0.55
RAB9A P51151 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
CYP19A1 P11511 2/20 0.54
CYP1A2 P05177 1/20 0.52
NOTUM Q6P988 1/20 0.52
MAPK14 Q16539 3/20 0.52
MAPK13 O15264 2/20 0.52
MAPK12 P53778 2/20 0.52
MAPK11 Q15759 2/20 0.52
KIF11 P52732 1/20 0.50
KDR P35968 1/20 0.49
PDGFRB P09619 1/20 0.48
PDGFRA P16234 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22137841 0.92 GCGR (0.59) GCGRLMNAMAPTLSSAKT1
SCHEMBL135626 0.84 MAPT (0.92) GCGRLMNAMAPTKDM4ESMN1; SMN2
SCHEMBL10000032 0.84 MAPT (0.92) GCGRLMNAMAPTKDM4ESMN1; SMN2
SCHEMBL3558118 0.83 GCGR (0.55) GCGRLMNAMAPTLSSAKT1
SCHEMBL6782503 0.82 PDGFRB (0.54) GCGRLMNAMAPTLSSAKT1
SCHEMBL4735385 0.81 CYP19A1 (0.57) GCGRLMNAMAPTLSSKDM4E
SCHEMBL14690989 0.81
SCHEMBL6842 0.81
SCHEMBL3952742 0.80 CYP1A2 (0.73) LMNARAB9ACYP1A2NOTUMKIF11
SCHEMBL28215 0.80 CYP1A2 (0.73) LMNARAB9ACYP1A2NOTUMKIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250099595-A1 HYDROGEL-BASED DELIVERY SYSTEM FOR INDUCTION OF INTRATUMORAL TERTIARY LYMPHOID STRUCTURES AND AUGMENTATION OF IMMUNE CHECKPOINT BLOCKADE AND METHODS THEREOF THE UNIVERSITY OF HONG KONG (CN) 2025-03-27 US claimed
CN-119656163-A Hydrogel-based delivery system and method for inducing intratumoral tertiary lymphoid structure and enhancing immune checkpoint blockade 香港大学 2025-03-21 CN claimed
CN-119409858-A Protonated product of pyridine derivative and compound, preparation method and application thereof 天津师范大学 2025-02-11 CN claimed
US-4533735-A Process for preparing antibacterial compounds ETHYL CORPORATION (US) 1985-08-06 US claimed
US-4405792-A Substituted pyridines and their preparation ETHYL CORPORATION (US) 1983-09-20 US claimed
US-20250099595-A1 HYDROGEL-BASED DELIVERY SYSTEM FOR INDUCTION OF INTRATUMORAL TERTIARY LYMPHOID STRUCTURES AND AUGMENTATION OF IMMUNE CHECKPOINT BLOCKADE AND METHODS THEREOF THE UNIVERSITY OF HONG KONG (CN) 2025-03-27 US disclosed
CN-119656163-A Hydrogel-based delivery system and method for inducing intratumoral tertiary lymphoid structure and enhancing immune checkpoint blockade 香港大学 2025-03-21 CN disclosed
CN-119409858-A Protonated product of pyridine derivative and compound, preparation method and application thereof 天津师范大学 2025-02-11 CN disclosed
CN-117586179-A GPR183 antagonist and synthetic method and application thereof 中国人民解放军海军特色医学中心 2024-02-23 CN disclosed
CN-117229111-A Dehydroaromatization method for aryl cyclic hydrocarbon 五邑大学 2023-12-15 CN disclosed
US-20230278996-A1 YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS MOLECURE S.A. (PL) 2023-09-07 US disclosed
US-20230278996-A1 YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS MOLECURE S.A. (PL) 2023-09-07 US disclosed
US-4604467-A Certain 4-(3,4-dibromocyclohexyl)pyridines ETHYL CORPORATION (US) 1986-08-05 US disclosed
US-4552963-A Preparation of 1-alkyl-1,4-dihydro-4-oxo-7-(4-pyridyl)-3-quinolinecarboxylic acid ETHYL CORPORATION (US) 1985-11-12 US disclosed
US-4552964-A 4-(1-Chlorocyclohex-3-enyl)pyridines and preparation of 1-alkyl-1,4-dihydro-4-oxo-7-(4-pyridyl)-3-quinolinecarboxylic acid ETHYL CORPORATION (US) 1985-11-12 US disclosed
US-4550167-A Preparation of 1-alkyl-1,4-dihydro-4-oxo-7-(4-pyridyl)-3-quinoline carboxylic acid ETHYL CORPORATION (US) 1985-10-29 US disclosed
US-4533735-A Process for preparing antibacterial compounds ETHYL CORPORATION (US) 1985-08-06 US disclosed
US-4490535-A 4-(3- and 4-Chlorocyclohex-3-enyl)pyridine intermediates ETHYL CORPORATION (US) 1984-12-25 US disclosed
US-4405792-A Substituted pyridines and their preparation ETHYL CORPORATION (US) 1983-09-20 US disclosed
US-4405792-A Substituted pyridines and their preparation ETHYL CORPORATION (US) 1983-09-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250099595-A1 HYDROGEL-BASED DELIVERY SYSTEM FOR INDUCTION OF INTRATUMORAL TERTIARY LYMPHOID STRUCTURES AND AUGMENTATION OF IMMUNE CHECKPOINT BLOCKADE AND METHODS THEREOF ICOS, CD274, LY96 GCGR 463/4885LMNA 4237/4885MAPT 3200/4885
US-20230278996-A1 YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS CHI3L1, CHI3L2, CHIA GCGR 2274/4885LMNA 3086/4885MAPT 2992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.